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Data suggest that individuals with schizophrenia (SZ) and superior intelligence can present
without specific neurocognitive deficits. However, neurocognitive decrements, defined
as worse cognition than expected, have been reported in practically all SZ cases. This
study investigated if neurocognitive decrements are present in intellectually superior SZ
by comparing the neuropsychological profile of SZ cases with IQ-matched healthy con-
trols (HC) across intellectual levels. Participants with SZ and HCs were stratified into three
IQ-groups; intellectually low (IQ 80–95; SZ n=65 and HC n=13), intellectually normal
(IQ=100–115; SZ n=111 and HC n=115), and intellectually superior (IQ≥120; SZ n=20
and HC n=50). A repeated measures multivariate analysis of co-variance compared perfor-
mance on eight selected neuropsychological tests across IQ-strata and diagnostic group.
Differences in clinical characteristics and social functioning in SZ across IQ-strata were
investigated with multivariate and univariate analyses of variance. Intellectually superior
SZ participants scored within normal limits, but had neurocognitive decrements compared
to superior HCs. Decrements were of the same magnitude as in the low and normal IQ-
strata. Levels of functional impairments and clinical characteristics in participants with SZ
did not differ significantly across IQ-strata. Results indicate that neurocognitive decrements
are present in intellectually superior SZ to the same extent as in intellectually low and intel-
lectually normal SZ, supporting the notion that SZ is a neurocognitive disorder. Similar levels
of social functional deficits and clinical symptoms suggest similar disease processes in SZ
across intellectual level.
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INTRODUCTION
Some individuals diagnosed with schizophrenia (SZ) perform
within the normal range on cognitive measures (1–3). This has
prompted research into the question of whether it is possible to
have SZ without neurocognitive impairment. In the 1990s and
2000s, the question was investigated in individuals with SZ who
had normal or near-normal scores on intelligence or neuropsycho-
logical tests. All of the studies found neurocognitive reductions.
These included a larger percentage with learning deficits in the
SZ sample compared to matched healthy control (HC) partic-
ipants (4), subclinical deficits and a neuropsychological profile
resembling the one seen in neurocognitively impaired SZ (5), neu-
rocognitive deficits compared to matched non-SZ clinical control
participants (6), higher verbal IQ and lower performance IQ (7),
or lower processing speed and memory scores (8) compared to
full scale IQ-matched HCs, and executive function and attention
deficits in SZ participants with preserved IQ (3). The existence of
neurocognitive reductions in individuals with SZ of average cog-
nitive abilities supports the notion that impaired neurocognition
is indeed a core feature of the disorder (9).
Later, the field has moved forward to studies of SZ samples with
superior intellectual abilities, asking the same question: Is there a
subgroup of individuals with SZ who are free of neurocognitive
impairment? Results have been mixed. Heinrichs and colleagues
(10) found that persons with SZ and verbal IQ≥ 90th percentile
did not differ from HC with equally superior verbal abilities on
any other neuropsychological measure, but they did require more
community support. MacCabe and co-authors (11) found that a
SZ group with both premorbid and current superior intelligence
did not differ from HC on any neuropsychological measure, but
speculated that subtle neurocognitive deficits may still be present
as the profile shape resembled those generally seen in SZ. Gray
et al. (12) found the same magnitude of neurocognitive differ-
ences between persons with SZ and HC across IQ-strata, including
those with WASI IQ> 120. All of these studies had methodologi-
cal limitations. They allowed for the inclusion of individuals with
schizoaffective disorder, two of them had quite small sample sizes
[(11): n= 10; (12): n= 7], and none were catchment area-based.
So far the presence of neurocognitive impairment in intellectually
superior SZ has not been thoroughly examined in a large, catch-
ment area-based, representative sample of both individuals with
a diagnosis of SZ and of healthy individuals. Our research set-
ting offers such an opportunity. In addition, we wanted to avoid
the inclusion of individuals with schizoaffective disorder in the SZ
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sample, as they are possibly characterized by better neurocognition
than SZ (13).
The overall goal of the current study is to explore whether SZ
with superior intellectual abilities is characterized by neurocogni-
tive deficits or decrements. In clinical neuropsychology, cognitive
impairment or deficit is usually defined based on performance
compared to a healthy reference sample (norms), often two stan-
dard deviations below the mean. In SZ research, one standard
deviation is often used (14). In order to capture the neurocogni-
tive impairment of SZ, cognitive function decrements have been
proposed as an alternative to deficits compared to norms (14).
Decrements are said to be present when cognitive performance
is worse than would be expected, e.g., compared to premorbid
estimates or general intelligence. Although many individuals with
SZ have normal and some above-normal intellectual or cogni-
tive abilities, Keefe et al. (14) found that 98% of individuals
with SZ performed worse than expected in various neurocog-
nitive domains and thus were characterized as having cognitive
decrements.
In the current study, individuals with SZ from different IQ-
strata are compared to HC within the same IQ-stratum. Three
SZ samples – with low, normal, and superior intellectual abil-
ities, respectively – are compared with three HC samples with
low, normal, and superior intellectual abilities. Such matching on
intelligence avoids confounding by a general deficit, and any subse-
quent SZ–HC difference will be due to deficits in specific cognitive
functions. We start by asking if intellectually superior SZ indi-
viduals are neuropsychologically impaired compared to standard
norms. Then we ask if the intellectually superior SZ sample is
significantly impaired on specific neurocognitive functions com-
pared to HCs with similar superior intellectual abilities. We end
this set of questions by asking whether the magnitude of decre-
ments in the intellectually superior SZ sample, should they exist,
differs from the magnitude of decrements seen for the two other
SZ samples when they are compared to their HC groups matched
for IQ-level.
Our main research question is: Does the magnitude of neu-
rocognitive SZ–HC differences vary across IQ-strata? Since the
question has been raised as to whether SZ with intact neurocog-
nition constitutes a less severe version of the disease (5), we
ask whether our three intellectually stratified SZ groups can be
distinguished on illness-related features, such as symptom load,
psychopharmacological treatment, illness duration, and social
functioning.
MATERIALS AND METHODS
PARTICIPANTS
The study was conducted within the multi-center Thematically
Organized Psychosis (TOP) Study at the University of Oslo, Nor-
way, from 2003 to 2012. Only participants with Norwegian as their
first language and/or all compulsory schooling in Norway and
Wechsler Abbreviated Scale of Intelligence [WASI; (15)] Full Scale
IQ≥ 70 were included in the current study. Two-hundred and
sixty-one persons aged 17–60 years with a Diagnostic and Statis-
tical Manual for Mental Disorders (fourth ed; DSM-IV) diagnosis
of SZ satisfied the inclusion criteria. Twenty-two of these indi-
viduals were excluded due to clinically significant head trauma
(n= 20), epilepsy (n= 1), or migraine (n= 1). In order to secure
a representative sample, individuals with concurrent substance
abuse were not excluded. However, none were assessed while under
influence of substances. The final SZ sample consisted of 239 indi-
viduals recruited from hospitals in the Oslo area. HCs from the
same geographical areas were recruited through national statisti-
cal records and invited by letter to participate. They were screened
with an interview to capture symptoms of severe mental illness
[Primary Care Evaluation of Mental disorders; PRIME-MD; (16)]
and excluded if there was any information on mental, neurological
or somatic disorder. The HC sample consisted of 456 individuals.
The TOP study is approved by the Regional Ethics Committee
and the Norwegian Data Inspectorate, and is completed in accor-
dance with the Helsinki Declaration. All participants received oral
and written information on the study and have signed informed
consent.
CLASSIFICATION OF SAMPLE
First, the HC sample was divided into two groups of equal
size (n= 228) using an online randomization tool (www.
randomization.com). The two HC groups did not differ in WASI
IQ, age, education, or sex distribution. HC group I was used as a
reference group for standardizing the neurocognition scores based
on their mean and standard deviation. HC group II was used in
the statistical analyses.
Second, the remaining sample (HC II n= 228; SZ n= 239)
was stratified into three IQ levels based on WASI Full Scale IQ:
intellectually low (IQ= 80–95), intellectually normal (IQ= 100–
115), and intellectually superior (IQ≥ 120). We chose IQ ranges
leaving a gap of five IQ-points between the three IQ levels to
avoid overlap between groups and increase the chances of tap-
ping true IQ-based strata. There were 65 individuals in the low
SZ group (SZ-low), 111 in the normal SZ group (SZ-normal)
and 20 in the superior SZ group (SZ-superior). Correspond-
ing numbers for HCs were 13 intellectually low (HC-low), 115
normal (HC-normal), and 50 intellectually superior individu-
als (HC-superior). The demographic characteristics of these six
groups are shown in Table 1. A multivariate analysis of vari-
ance (MANOVA) showed significant overall effects of the demo-
graphic variables. Education differed across diagnostic group
(F (1, 368)= 14.9, p< 0.001, η2= 0.04) and intellectual level (F
(2, 368)= 26.8, p< 0.001, η2= 0.13), whereas age (F = 5.5 (1, 368),
p< 0.020,η2= 0.02) and sex (F (1, 368)= 6.1, p< 0.014,η2= 0.02)
differed across diagnostic group.
CLINICAL AND SOCIAL FUNCTION ASSESSMENT
The SZ sample was assessed with the Positive and Negative Syn-
drome Scale [PANSS; (17)] and the Inventory of Depressive
Symptomatology-Clinician rated [IDS-C; (18)]. To enable analysis
of antipsychotic drug treatment across antipsychotic medications,
we calculated the defined daily dose (DDD), which is the assumed
average maintenance dose per day for a drug used for its main
indication in adults. For example, someone receiving one antipsy-
chotic medication with half the recommended dose has a DDD
of 0.5, whereas someone who receives two antipsychotic med-
ications, each with 80% of recommended dose, gets a DDD of
1.6. Global functioning was assessed with the Global Assessment
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Table 1 | Demographic characteristics in schizophrenia and healthy participant groups and clinical characteristics in participants with
schizophrenia.
SZ-low IQ,
n=65
HC-low IQ,
n=13
SZ-normal IQ,
n=111
HC-normal IQ,
n=115
SZ-superior IQ,
n=20
HC-superior IQ,
n=50
Statistics
(F -values)
Age 31.8 (11.7) 34.4 (12.3) 30.0 (8.4) 36.6 (10.6) 30.9 (6.4) 31.4 (8.2) Group: 5.5*
18–60 18–53 17–57 18–55 22–42 19–51
Education 10.9 (1.8) 12.1 (1.3) 12.5 (2.2) 13.6 (2.3) 14.0 (2.5) 15.0 (1.8) Group: 14.9**
9–16 10–14 9–18 9–18 9–18 11–18 IQ: 26.8**
Gender (males/females) 39/26 6/7 66/45 49/66 15/5 27/23 Group: 6.1*
WASI IQ 88.2 (4.3) 90.4 (4.4) 107.3 (4.5) 108.6 (4.4) 126.4 (4.1) 126.0 (4.0) IQ: 850.9**
PANSS 16.1 (5.1) – 14.9 (5.5)b – 15.4 (5.9)e – ns
Positive symptoms scale
PANSS 16.9 (6.3) – 15.8 (6.5)c – 16.2 (6.7)e – ns
Negative symptoms scale
IDS-C 18.7 (12.3)a – 15.1 (10.8)d – 16.0 (10.1)f – ns
GAF-symptoms 38.3 (9.9) – 41.4 (10.4) – 43.8 (10.8) – ns
Age of psychosis onset 23.8 (10.1) – 23.1 (7.5) – 23.9 (5.8) – ns
n=63 n=108
Illness duration 8.3 (8.3) – 7.0 (6.2) – 7.0 (6.2) – ns
n=63 n=108
Average defined daily dose
antipsychotics
1.42 (1.71) – 1.36 (0.82) – 1.32 (1.27) – ns
n=56 (86%) n=103 (93%) n=15 (75%)
Level of care (inpatient/outpatient) 21/44 (32/68%) – 25/86 (23/77%) – 3/17 (15/85%) – ns
GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale; IDS-C, Inventory of Depressive Symptomatology-Clinician rated.
an=49, bn=109, cn=110, dn= 92, en=19, fn=15,
*p<0.05, **p<0.01.
of Functioning Scale-split version (19). In this version the GAF
scale is divided into one symptom and one function score. It
was used in order to improve psychometric properties. Social
adjustment was assessed with the Social Functioning Scale [SFS;
(20)]. SFS consists of seven subscales covering areas such as social
engagement, independence, prosocial activities, and work func-
tion. SFS results are given in standardized scores (mean in SZ
samples= 100, standard deviation= 15). Data are presented in
Tables 1 and 4.
NEUROPSYCHOLOGICAL ASSESSMENT
All participants completed a battery of standard neuropsycholog-
ical tests when in a clinically stable state. Intelligence was assessed
with the four-subtest WASI. In addition, five neuropsychologi-
cal tests were chosen for the present study. Fine motor function
was assessed with the Grooved Pegboard Test (21). Psychomo-
tor speed was assessed with the Wechsler Adult Intelligence Scale
[third version, WAIS-III; (22)] Digit Symbol subtest, and attention
with WAIS-III Digit Span (combined score forward and back-
ward). Verbal learning was measured using the Logical Memory
Test [Wechsler Memory Scale 3rd version; WMS-III; (23)]. Sub-
tests from the Delis–Kaplan Executive Function System [D-KEFS;
Delis (24)] yielded scores for inhibition (Color-Word Interfer-
ence test; “Stroop” condition), phonemic (Letter fluency/FAS)
and semantic verbal fluency (Category fluency/Animals and Boys’
Names), and cognitive flexibility (Category Switching/Fruits and
Furniture – number of correct responses).
STATISTICAL ANALYSIS
The Statistical Package for the Social Sciences (IBM SPSS Statistics
for Windows, Version 20.0, IBM Corp., Armonk, NY, USA) was
used. A two-way repeated measures MANCOVA of the effect of
group membership (SZ or HC) and intellectual level (low, normal,
superior) on neurocognition was conducted. The eight standard-
ized neuropsychological test scores were entered as dependent
variables (within-subjects factor). Group (SZ or HC) and intellec-
tual level (low, normal, superior) were the between-subject factors.
A significant interaction between group membership and intellec-
tual level will indicate that the magnitude of SZ–HC differences
varies across intellectual level. Since initial analyses found sex and
age to differ across diagnostic groups and intellectual level, these
two variables were entered as covariates. Although the groups dif-
fered in education, it was not included as a covariate as education
is linked to our two study variables (SZ and intellectual level),
i.e., inherent to the groups being considered. Follow-up univariate
analyses of covariance (ANCOVAs) were conducted for each neu-
ropsychological test and effect sizes (Cohen’s d) for SZ–HC differ-
ences were calculated for all neuropsychological (raw) test scores
using the pooled standard deviation for the IQ-stratum in ques-
tion. We also provide effect sizes for overall SZ–HC differences,
across IQ-strata.
An additional two-way repeated measures MANCOVA (con-
trolling for age and sex) was conducted to investigate effects
of group and intellectual level on social function as assessed
with the seven SFS subscales (within-subjects factor). It was
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followed by univariate analyses of variance (ANCOVA) for group
and intellectual level for each of the seven SFS subscales. Dif-
ferences in functioning between the SZ groups assessed with
GAF-f were investigated with a univariate analysis of variance
(ANOVA).
Finally, the presence of any differences in symptom load
between SZ-superior and the other SZ groups was investigated
with a one-way MANOVA with subsequent follow-up ANOVAs
in the case of significant overall effects. Variables analyzed were
symptoms as assessed with PANSS, IDS-C, and GAF-s. Differences
in age of onset, illness duration, and DDD of antipsychotic med-
ications were analyzed with three separate ANOVAs. Differences
in level of care, i.e., the number of participants receiving inpatient
versus outpatient treatment across IQ-strata, were examined with
a chi-square test for independence.
RESULTS
The standardized neuropsychological test scores for the intellec-
tually superior SZ sample are presented in Table 2 (and Figure 1).
Although below mean, the group performs well within the normal
range compared to the standardization sample (HC I).
The magnitude of neurocognitive SZ–HC differences did not
differ across IQ-strata (see Table 3). The repeated measures
MANCOVA for the eight standardized neuropsychological test
scores yielded a significant overall main effect of neuropsy-
chological test [F (7, 350)= 8.0, p< 0.001, Wilk’s Lambda= 0.86,
η2= 0.14], indicating that performance differs across tests. The
interaction effects between neuropsychological test and group
[F (7, 350)= 12.0, p< 0.001, Wilk’s Lambda= 0.81, η2= 0.19]
and between neuropsychological test and intellectual level [F
(14, 702)= 7.8, p< 0.001,Wilk’s Lambda= 0.75,η2= 0.13], respec-
tively, were significant. In other words, the neuropsychologi-
cal profile differs between SZ and HC and between individu-
als of different intellectual levels. Finally, the interaction effect
between neuropsychological test, group, and intellectual level was
non-significant [F (14, 700)= 1.1, p= 0.350, Wilk’s Lambda= 0.96,
η2= 0.02]. Differences in neurocognitive performance were con-
sistent across IQ-strata as was the shape of the neuropsychological
profile (see Figure 1). As expected, follow-up ANCOVAs yielded
non-significant interaction effects (reported in Table 3). Effect
Table 2 | Neuropsychological performance in participants with
schizophrenia and superior intellectual abilities
(n=20) – standardized scores (z) based on the reference sample.
M (SD)
Grooved pegboard −0.42 (0.96)
Digit symbol −0.30 (0.89)
Digit span −0.24 (0.77)
Logical memory learning −0.24 (1.25)a
Phonemic fluency −0.07 (0.96)
Semantic fluency −0.43 (1.04)
Category switching −0.25 (0.85)
Inhibition −0.20 (1.09)
an=18.
sizes (see Table 3) for overall SZ–HC differences were largest for
processing speed and semantic fluency, and smallest for inhibition,
attention, and phonemic fluency. IQ-stratified effect sizes ranged
from medium-sized to large for intellectually superior partici-
pants, from small to large for participants with normal intelligence
and from small to large for intellectually low participants, using
Cohen’s rules of thumb (25).
IQ-level had no effect on social function (see Table 4). The over-
all repeated measures MANCOVA for social function as assessed by
the SFS yielded a significant main effect of the social function scales
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FIGURE 1 | Neuropsychological profile of schizophrenia and healthy
participant groups. (1) Fine motor function/Grooved Pegboard Test; (2)
psychomotor speed/digit symbol; (3) attention/digit span; (4) Verbal
learning/Logical Memory Test; (5) phonemic fluency/letter fluency; (6)
semantic fluency/category fluency; (7) cognitive flexibility/category
switching; (8) inhibition/“Stroop” z -scores were calculated based on the
performance of HC group I.
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Table 4 | Social functioning in schizophrenia and healthy participant groups.
SZ-low,
n=60
HC-low,
n=13
SZ-normal,
n=103
HC-normal,
n=114
SZ-superior,
n=18
HC-superior,
n=49
ANCOVA
Group,
F -value
IQ,
F -value
Group× IQ,
F -value
SFS 1: withdrawal/social
engagement
99.4 (12.4) 120.1 (7.5) 101.8 (10.3) 121.3 (8.5) 98.1 (8.7) 120.6 (9.7) 197.4** 0.9 0.7
SFS 2: interpersonal
communication
109.2 (16.9) 136.9 (10.6) 114.0 (17.8) 139.6 (11.2) 118.4 (21.3) 137.3 (13.1) 110.6** 1.6 1.2
SFS 3: independence-
performance
102.4 (11.8) 116.0 (9.7) 104.0 (11.8) 117.1 (8.6) 105.1 (11.3)e 118.6 (7.1) 68.1** 1.9 0.2
SFS 4: independence-
competence
106.0 (12.8) 123.0 (0) 110.3 (11.1) 122.3 (3.2) 111.4 (10.9) 122.2 (3.1) 109.5** 1.1 1.9
SFS 5: recreation 103.7 (15.3) 127.2 (11.6) 105.2 (14.7) 126.9 (12.5) 108.8 (14.4) 124.8 (12.9) 93.6** 0.5 0.8
SFS 6: prosocial activities 101.4 (15.0) 125.3 (9.7) 106.8 (12.6) 123.8 (10.0) 102.7 (11.5) 125.3 (8.6) 148.8** 0.6 2.3
SFS 7: employment/
occupation
101.7 (11.8) 121.5 (2.4) 103.6 (11.2)b 122.0 (2.4)d 107.4 (10.6) 121.1 (5.2) 211.6** 1.0 2.4
GAF-function 40.7 (8.9)a – 42.9 (9.9)c – 42.6 (8.9)f – – 1.1 (ANOVA) –
SFS, Social Functioning Scale.
an=65, bn=102, cn=111, dn=113, en=17, fn=20.
**p<0.01, *p<0.05.
[F (6, 341)= 16.5, p< 0.001, Wilk’s Lambda= 0.78, η2= 0.23] as
well as of the interaction effect between social function scales
and group [F (6, 341)= 8.1, p< 0.001, Wilk’s Lambda= 0.88,
η2= 0.13]. The interaction between social function scales and
intellectual level was non-significant [F (12, 682)= 0.9, p= 0.523,
Wilk’s Lambda= 0.97, η2= 0.02]. The interaction effect between
social function scales, group, and intellectual level just reached sig-
nificance with a small effect size [F (12, 686)= 1.8, p= 0.041, Wilk’s
Lambda= 0.94, η2= 0.03]. Follow-up ANCOVAs for each of the
seven SFS scales yielded only significant effects of group (SZ or
HC), not of intellectual level or of the interaction between group
and intellectual level (see Table 4). The results from the ANOVA
for the GAF-f scores in the three SZ groups were non-significant.
Finally, there were no clinical differences across IQ-strata
among individuals with SZ. The three SZ groups had very similar
symptom scores (see Table 1), and the overall MANOVA yielded
no significant group differences [F (8, 294)= 0.7, p= 0.655, Wilk’s
Lambda= 0.96, η2= 0.02]. Similarly, no significant group differ-
ences appeared for age of onset, illness duration, daily dosage
of antipsychotic medication, or in level of care, although rela-
tively fewer persons in the superior sample used antipsychotic
medications or received inpatient care.
DISCUSSION
This study found neurocognitive decrements in a group of intel-
lectually superior SZ participants compared to an intellectually
superior HC group. The magnitude of the decrements was simi-
lar to those found for intellectually normal and intellectually low
SZ. So, answering our first research question, the magnitude of
neurocognitive SZ–HC differences does not vary across IQ-strata.
Our results are in line with previous findings of no variation in
the overall magnitude of neurocognitive differences between SZ
participants and HC of different IQ-strata (12), of similar neu-
ropsychological profile in participants with SZ across intellectual
level (11), and of reduced social functioning in SZ participants
with superior intelligence (10). Overall, the current literature sup-
ports the presence of neurocognitive decrements in intellectually
superior SZ, although diverging results exist (10). One reason that
some previous studies (11) did not find statistically significant
neuropsychological differences between SZ participants and IQ-
matched HC could be small sample sizes and lack of statistical
power.
None of the neuropsychological test results of the intellectually
superior SZ group fell below the normal range using standardized
scores (>1 standard deviation). Thus, according to an approach
typically used in clinical neuropsychology, they have no neurocog-
nitive deficits. Therefore, one could say that it is possible to have
SZ and be neuropsychologically normal. However, this approach
masks the decrements readily visible in the figure and that our
statistical approach exposed. Visual inspection of the scores in
Figure 1 reveals two important findings. First, although within
what is considered the normal range when compared to a normal
control group not stratified based on intelligence, this intellectu-
ally superior SZ group, nevertheless, performs below the mean
on all tests. Further, their performance is below what would be
expected based on their IQ more than a standard deviation above
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the mean. This discrepancy constitutes further evidence for the
existence of neurocognitive decrements in intellectually superior
SZ. Consequently, it seems more correct to say that it is possible to
have SZ and be neuropsychologically normal, but only if you have
superior intellectual abilities – and it is not possible to be neu-
ropsychologically superior, even if you have superior intellectual
abilities.
The overall SZ–HC effect sizes are much as we know from
the broader literature (26) with larger impairments for process-
ing speed (Digit Symbol) and semantic fluency (Category fluency),
and smaller impairments for attention (Digit Span) and phone-
mic fluency (Letter fluency/FAS). For the intellectually superior
SZ sample, the largest effect sizes were seen for cognitive flexibility
(Category Switching) and fine motor function (Grooved Pegboard
Test). A large effect size was also seen for semantic fluency. This
was also the test that deviated most from the mean of HC group
I using standardized scores (−0.43). After semantic fluency, fine
motor function showed the largest deviation from the HC I mean
(−0.42), corroborating the finding from the statistical analyses.
Neuromotor abnormalities (27) as well as impaired psychomo-
tor speed are present and central in SZ (28, 29). The Grooved
Pegboard test is dependent upon both skills. Our measures of
cognitive flexibility and semantic fluency are subtests from the
same verbal fluency measure and can be considered measures of
semantic memory that depend upon accessing the semantic store.
Findings of impaired category fluency are robust in SZ (30). This
impairment could be due to problems with the store (semantic
memory) or with accessing it (retrieval which involves executive
functioning). Persons with SZ show abnormal clustering on cate-
gory fluency tasks suggesting a degraded store. On the other hand,
similar levels of impairment in phonemic and semantic fluency
indicate executive impairment, as does slow or reduced switch-
ing between categories – both of which are seen in SZ samples
in general (30) as well in our sample (medium-to-large effect size
for phonemic fluency). Thus, impaired semantic memory in SZ
involves executive function. In other words, the superior sample
in our study has, in spite of their superior IQ, neurocognitive prob-
lems that are very common in individuals with SZ – with motor
function, speeded processing, semantic memory, and executive
function. A recent large review and meta-analysis of cognitive
studies from around the world, spanning several decades (26),
found the largest impairments for episodic memory, speed of pro-
cessing and semantic fluency, and relatively smaller impairments
for measures of intelligence. We found this pattern to hold true
within IQ-stratified groups as well as for the overall sample, across
IQ-strata.
Our second research question concerned differences in illness-
related features across IQ-strata within the SZ sample. We found
no evidence of such differences. Similar functional impairments,
similar levels of both psychotic and depressive symptoms and of
daily dosage of antipsychotic medications were observed. Thus,
our results are in line with previous reports indicating weak associ-
ations between neurocognition and clinical symptoms (31). It has
been proposed that the SZ disease process could differ between
individuals who differ in neurocognitive performance (32) and
that neurocognitively intact SZ constitutes a less severe form of the
disease (5). We found no support for such hypotheses, although
we do acknowledge that there were indeed fewer in the intellec-
tually superior SZ sample that used antipsychotic medications or
who received treatment in inpatient facilities. In spite of this, hav-
ing intellectual abilities well above the population mean does not
offer protection against the everyday problems and the suffering
associated with SZ. Thus, although they have superior intellectual
abilities, this group seems unable to utilize this asset by trans-
ferring it to better coping with the challenges of everyday life.
The results of an early study on monozygotic twins discordant
and concordant for SZ are in line with this finding (33). In that
study, levels of social and vocational impairments were similar and
reduced in all affected cases, but intact in non-affected discordant
monozygotic twins. However, subtle neurocognitive impairments
were found in the non-affected twins. One interpretation of such
findings is that social impairments are a disease-specific factor,
whereas impairments in cognition might be a genetic vulnerability
marker. In our cognitively diverse SZ sample, there must be other
predictors of functioning besides neurocognition at play. Indeed,
neurocognition does not always predict functional outcome, as we
have previously shown for a non-overlapping first-episode psy-
chosis sample (34). Other possible predictors, known to impact
functioning, are of an internal nature such as social cognition
(35) or dysfunctional beliefs (36). External, societal factors such as
availability of health and employment services may also influence
functioning. These factors were not investigated in the current
study.
Limitations of this study include the cross-sectional design and
the lack of information on premorbid intellectual function. Intel-
lectual decline has been demonstrated for SZ (37), and it is quite
possible that our participants have deteriorated from premor-
bid levels. Further, as the study addressed group comparisons,
the existence of a single individual with comparable and superior
neurocognitive and intellectual abilities is possible. Additionally,
we only included treatment-seeking individuals with SZ. The exis-
tence of a separate subgroup of very high-functioning individuals
with SZ that are not in contact with the mental health services, and
that we therefore were not able to get hold of given our recruitment
strategy, cannot be ruled out. Also, our subtyping approach yielded
unequal cell sizes with few cases in the low (HC) and superior (SZ)
IQ-strata. This is a limitation of the study, but the rule-of-thumb of
having more cases in each cell than number of dependent variables
was not violated (13 participants in the cell with the fewest cases
versus eight neuropsychological tests). Another statistical concern
is that our results are simply a reflection of regression toward the
mean. Although we cannot be sure that this is not the case, we also
note that the idea of regression to the mean as a causal explanation
for change or difference in scores has been heavily criticized from a
statistical standpoint and even called out as a myth (38). According
to these authors, the idea that a second score will invariably be less
extreme than the first score (in our case that a person with SZ who
was selected on the basis of an extremely high IQ score will auto-
matically present with lower neuropsychological test scores) has
taken the form of a law. They warn of treating regression toward
the mean as a causal agent on an individual’s score. Strengths of
our study include the use of a catchment area-based approach for
the recruitment of a large representative sample of both healthy
and ill individuals, the exclusion of individuals with schizoaffective
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disorder, the matching of HC based on IQ-strata, and assessment
with a large neuropsychological test battery.
In summary, our study supports the view that people with SZ
and superior intelligence have neurocognitive decrements when
compared to a relevant control group, i.e., matched on IQ. There-
fore, the study also supports the notion of the “primacy of cogni-
tion in SZ”(39). Further, similar levels of symptoms and functional
impairments across the intellectual spectrum indicate that intel-
lectually superior SZ is not a separate disease entity or a less severe
type of SZ. Such findings lend support to the idea that cognition
is a central characteristic of the disorder and that using neurocog-
nition as a biomarker in genetic studies is warranted. The findings
also underline the importance of looking at relative decrements,
even in persons with superior abilities. The door is open for explo-
ration of whether cognitive-enhancing treatment could be useful
also for this group.
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